Eloralintide Results Timeline: What Studies Measured, and When

Eloralintide (development code LY3841136) is an investigational, long-acting, selective amylin receptor agonist that has been studied in the context of obesity, as described by researchers in a paper tracing the molecule from discovery to clinical proof of concept (PMID 41109426). Questions about "when results appear" are, in the published record, really questions about study duration and endpoint schedule: how long each trial ran, in whom, and what the investigators chose to measure along the way. This page walks that timeline as the literature describes it. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or any investigational compound.

The shape of the published timeline

The eloralintide evidence base, as of the papers indexed here, spans three distinct layers. The earliest layer is preclinical and translational: researchers reported a discovery-to-clinical-proof-of-concept account of eloralintide as a novel amylin receptor agonist for obesity (PMID 41109426), which is the paper that covers the non-human pharmacology and the bridge into first-in-human work. The second layer is early clinical: a phase 1 proof-of-concept report described eloralintide as a selective, long-acting amylin receptor agonist for the treatment of obesity (PMID 41559929). The third layer is the longest human exposure currently published: a 48-week, phase 2, multicentre, double-blind, randomised, placebo-controlled trial in obesity (PMID 41207310).

Around those primary reports sit secondary sources that summarise the class rather than generate new timepoints: a review of long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (PMID 41747885), a review of amylin analogs covering experimental data and early-phase clinical trials (PMID 42452898), and a network meta-analysis of novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes (PMID 42175595).

Timepoints at a glance

Layer one: preclinical and discovery work (labelled as such)

Before any human timeline existed, the molecule had to be characterised in non-clinical models. The discovery-to-proof-of-concept report described eloralintide as a novel amylin receptor agonist developed for obesity and traced that development sequence explicitly (PMID 41109426). Work of this kind is not a results timeline for people: readers should treat receptor pharmacology and animal model findings as mechanism-generating rather than as a schedule of human outcomes, and the class reviews make the same distinction when they separate experimental data from early-phase clinical trials (PMID 42452898).

The broader amylin literature frames why selectivity mattered at the discovery stage. Researchers reviewing long-acting amylin-related peptides positioned them as candidate therapies for obesity and type 2 diabetes, a framing that explains why a selective amylin receptor agonist was pursued rather than a broader multi-receptor construct (PMID 41747885).

Layer two: the phase 1 window

The first human timepoints in the published record come from phase 1. Researchers reported a phase 1 proof-of-concept evaluation of eloralintide described as a selective, long-acting amylin receptor agonist for the treatment of obesity (PMID 41559929). Phase 1 programmes in this class conventionally concentrate on safety, tolerability and pharmacokinetics before any durable efficacy question is asked, and the same molecule's translational account described the transition into clinical proof of concept in those terms (PMID 41109426).

What this layer does not provide is a long-horizon answer. Early-phase exposure windows are short by design, and reviews of amylin analogs have repeatedly flagged that early-phase clinical trials sit at a different evidentiary level from longer randomised comparisons (PMID 42452898).

Layer three: the 48-week phase 2 trial

The longest published human window for eloralintide is 48 weeks. The study was reported as a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial of eloralintide as a selective amylin receptor agonist for the treatment of obesity (PMID 41207310). Each design element carries information about when and how anything was measured:

• 48 weeks defines the maximum randomised follow-up reported for the compound in that trial (PMID 41207310).
• Placebo-controlled means any change described in the trial was referenced against a concurrent placebo group rather than against baseline alone (PMID 41207310).
• Double-blind means participants and investigators were masked to allocation across that 48-week window (PMID 41207310).
• Multicentre means recruitment spanned multiple sites rather than a single clinic population (PMID 41207310).
• Phase 2 means the trial sat at the dose-finding and preliminary-efficacy stage rather than the confirmatory stage, consistent with how reviews of this class describe the current evidence position (PMID 42586227).

Because peptideu.co reports only what the verified literature states, no week-by-week percentage, kilogram figure or dose is asserted here. Readers seeking the numeric endpoint values reported by researchers can consult the primary trial report directly (PMID 41207310).

In whom the 48-week trial was conducted

The phase 2 trial was described as a study in obesity (PMID 41207310). A separate network meta-analysis specifically addressed novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes, which is a narrower population framing than the class reviews that also discuss type 2 diabetes (PMID 42175595). The distinction matters when interpreting timelines, because a population enrolled without diabetes is not interchangeable with one enrolled with it, a point reflected in reviews covering both indications for long-acting amylin-related peptides (PMID 41747885).

Tolerability and Adverse Events: What Studies Report

Tolerability is one of the categories assessed earliest in a development programme and tracked continuously thereafter. The phase 1 proof-of-concept report of eloralintide was framed around early clinical characterisation of a selective, long-acting amylin receptor agonist (PMID 41559929), and the 48-week randomised, double-blind, placebo-controlled phase 2 trial provided a placebo comparator against which adverse events over that longer window were assessed (PMID 41207310).

At the class level, a pharmacological review framed amylin-based pharmacotherapy explicitly around the search for better-tolerated weight-loss drugs, which signals that tolerability — not efficacy alone — has been a central research question for this mechanism (PMID 42586227). A separate perspective on next-generation metabolic modulators discussed both the promise and the controversies surrounding multi-receptor and novel agonist approaches in obesity pharmacotherapy (PMID 41948476). Specific adverse-event rates, severities and discontinuation figures are reported in those source documents and are not restated here.

Cardiometabolic endpoints: an emerging, not established, timeline

A commentary in the cardiology literature addressed cardiometabolic risk reduction through selective amylin receptor agonism and described the cardiovascular implications of eloralintide as emerging (PMID 42745233). That framing is important for anyone reading a timeline: a narrative discussion of potential cardiovascular relevance is a different object from a dedicated cardiovascular outcomes trial, and no such outcomes trial for eloralintide appears among the verified reports summarised on this page (PMID 42745233).

How the class syntheses handle timing

Meta-analytic and review work compresses multiple trial durations into a single comparison, which is useful for ranking but can obscure differences in follow-up length. The network meta-analysis of novel amylin-based therapies pooled evidence in adults with overweight or obesity without diabetes rather than reporting a single fixed timepoint for every agent (PMID 42175595). Reviews of amylin analogs similarly aggregated experimental data alongside early-phase clinical trials, spanning very different evidence maturities in one document (PMID 42452898). Broader perspective articles on obesity pharmacotherapy placed these agents within a wider landscape of multi-receptor agonists and next-generation metabolic modulators, and flagged ongoing controversies in that field (PMID 41948476).

What the published record does not currently answer

1. Beyond 48 weeks. The longest randomised duration described in the verified reports is the 48-week phase 2 trial, so durability past that window is not characterised by that study (PMID 41207310).
2. Confirmatory phase 3 outcomes. The available primary reports are phase 1 and phase 2, and class reviews continue to describe amylin analogs in terms of experimental data and early-phase clinical trials (PMID 42452898).
3. Cardiovascular event outcomes. Cardiovascular relevance was described as emerging in review form rather than demonstrated in an outcomes trial (PMID 42745233).
4. Head-to-head certainty. Comparative positioning against other agents came from indirect network meta-analysis rather than direct randomised comparison (PMID 42175595).
5. Individual trajectories. Trial-level averages described by researchers do not describe what any single person would experience, and reviews of the class emphasise tolerability variability as an open question (PMID 42586227).

Reading a timeline responsibly

A "results timeline" in clinical research is a description of when investigators looked, not a forecast of when anything happens. For eloralintide, the sequence in the published literature moved from discovery and translational characterisation (PMID 41109426), to phase 1 proof of concept (PMID 41559929), to a 48-week randomised placebo-controlled phase 2 trial (PMID 41207310), with reviews and a network meta-analysis interpreting that record for the wider amylin class (PMID 42175595). Eloralintide is an investigational compound; nothing on this page describes an approved use, and no timing, regimen or administration guidance is provided. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question relating to obesity treatment or investigational drugs.

References

• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (Lancet, 2025)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (Diabetes, Obesity & Metabolism, 2026)
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (Peptides, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials (Diabetes, Obesity & Metabolism, 2026)
• Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis (Endocrinology, Diabetes & Metabolism, 2026)
• Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide (Cardiology in Review, 2026)